Spots Global Cancer Trial Database for advanced lymphoma
Every month we try and update this database with for advanced lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) | NCT04439227 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Adavosertib | 18 Years - | National Cancer Institute (NCI) | |
| A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | NCT05279300 | Advanced Solid ... Advanced Lympho... | CS5001 | 18 Years - | CStone Pharmaceuticals | |
| Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) | NCT04439344 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Binimetinib | 18 Years - | National Cancer Institute (NCI) | |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) | NCT04439149 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | PI3K-beta Inhib... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) | NCT04439318 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | NCT04439240 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas... | FGFR Inhibitor ... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) | NCT04439344 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Binimetinib | 18 Years - | National Cancer Institute (NCI) | |
| Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) | NCT06357988 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Echocardiograph... Radionuclide Im... Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| First in Human, Dose Escalation Study of AN4005 | NCT04999384 | Advanced Solid ... Advanced Lympho... | AN4005-dose lev... AN4005-dose lev... AN4005-dose lev... AN4005-dose lev... AN4005-dose lev... AN4005-food eff... | 18 Years - | Adlai Nortye Biopharma Co., Ltd. | |
| Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) | NCT04439123 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Capivasertib | 18 Years - | National Cancer Institute (NCI) | |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) | NCT04439357 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas | NCT05053971 | Advanced Lympho... Advanced Malign... Advanced Pancre... B-Cell Non-Hodg... Metastatic Panc... Refractory B-Ce... Refractory Lymp... Refractory Mali... Refractory Panc... Refractory T-Ce... Stage II Pancre... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | BET Bromodomain... Core Biopsy Entinostat | 18 Years - | National Cancer Institute (NCI) | |
| Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) | NCT06390826 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... Sunitinib | 18 Years - | National Cancer Institute (NCI) | |
| Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) | NCT04439175 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Taselisib | 18 Years - | National Cancer Institute (NCI) | |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) | NCT04439149 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | PI3K-beta Inhib... | 18 Years - | National Cancer Institute (NCI) | |
| Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) | NCT06400225 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... Ulixertinib | 18 Years - | National Cancer Institute (NCI) | |
| Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) | NCT04439331 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Defactinib Hydr... | 18 Years - | National Cancer Institute (NCI) | |
| Studying TAK-243 in Patients With Advanced Cancer | NCT06223542 | Advanced Lympho... Advanced Malign... Metastatic Mali... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... UAE Inhibitor T... | 18 Years - | National Cancer Institute (NCI) | |
| Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | NCT03925428 | Advanced Lympho... Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Refractory B-Ce... Refractory Lymp... Refractory Mali... Refractory Panc... Refractory T-Ce... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Entinostat Molibresib | 12 Years - | National Cancer Institute (NCI) | |
| Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) | NCT06400225 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... Ulixertinib | 18 Years - | National Cancer Institute (NCI) | |
| Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) | NCT04439201 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... | Palbociclib | 18 Years - | National Cancer Institute (NCI) | |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) | NCT04439279 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | NCT04439240 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas... | FGFR Inhibitor ... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) | NCT06400264 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Nivolumab Relatlimab | 18 Years - | National Cancer Institute (NCI) | |
| First in Human, Dose Escalation Study of AN4005 | NCT04999384 | Advanced Solid ... Advanced Lympho... | AN4005-dose lev... AN4005-dose lev... AN4005-dose lev... AN4005-dose lev... AN4005-dose lev... AN4005-food eff... | 18 Years - | Adlai Nortye Biopharma Co., Ltd. | |
| Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) | NCT04439175 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Taselisib | 18 Years - | National Cancer Institute (NCI) | |
| Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) | NCT06400251 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) | NCT04439227 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Adavosertib | 18 Years - | National Cancer Institute (NCI) | |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) | NCT06360575 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Crizotinib Radiologic Exam... | - | National Cancer Institute (NCI) | |
| Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) | NCT04439110 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Trastuzumab Emt... | 18 Years - | National Cancer Institute (NCI) | |
| Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) | NCT06308822 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Erdafitinib Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) | NCT04439292 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Dabrafenib Mesy... Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies | NCT04470947 | Advanced Lympho... Refractory Lymp... Refractory Leuk... Refractory Acut... Refractory T-Ce... | Next generation... Comprehensive g... | 18 Years - | Medical University of Vienna | |
| Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) | NCT04439253 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Crizotinib | 18 Years - | National Cancer Institute (NCI) | |
| Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) | NCT04439201 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... | Palbociclib | 18 Years - | National Cancer Institute (NCI) | |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) | NCT06357975 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Crizotinib Radiologic Exam... | 18 Years - | National Cancer Institute (NCI) | |
| Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) | NCT06303167 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Echocardiograph... Multigated Acqu... Osimertinib Radiologic Exam... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C) | NCT06390839 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Palbociclib | 18 Years - | National Cancer Institute (NCI) | |
| Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) | NCT04439136 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Afatinib Dimale... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C) | NCT06390839 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Palbociclib | 18 Years - | National Cancer Institute (NCI) | |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) | NCT06385496 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) | NCT04439136 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Afatinib Dimale... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) | NCT05490771 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Computed Tomogr... Copanlisib Hydr... Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) | NCT06390865 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | NCT02465060 | Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ... | Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) | NCT04439266 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Crizotinib | 18 Years - | National Cancer Institute (NCI) | |
| Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) | NCT06385483 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Afatinib Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... | 18 Years - | National Cancer Institute (NCI) | |
| Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) | NCT06303167 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Echocardiograph... Multigated Acqu... Osimertinib Radiologic Exam... | 18 Years - | National Cancer Institute (NCI) | |
| Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) | NCT06390852 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Larotrectinib Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) | NCT04439214 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas... | Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) | NCT04439201 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... | Palbociclib | 18 Years - | National Cancer Institute (NCI) | |
| Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers | NCT01563302 | Advanced Cancer... DLBCL Lymphoma | IONIS-STAT3Rx | 18 Years - | Ionis Pharmaceuticals, Inc. | |
| Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) | NCT06303167 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Echocardiograph... Multigated Acqu... Osimertinib Radiologic Exam... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) | NCT04439292 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Dabrafenib Mesy... Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) | NCT06360575 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Crizotinib Radiologic Exam... | - | National Cancer Institute (NCI) | |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) | NCT04439188 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | PI3K-beta Inhib... | 18 Years - | National Cancer Institute (NCI) | |
| Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies | NCT04470947 | Advanced Lympho... Refractory Lymp... Refractory Leuk... Refractory Acut... Refractory T-Ce... | Next generation... Comprehensive g... | 18 Years - | Medical University of Vienna | |
| Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) | NCT04439214 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas... | Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) | NCT06385496 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) | NCT04439305 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas... | Dasatinib | 18 Years - | National Cancer Institute (NCI) | |
| Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C) | NCT06390839 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Palbociclib | 18 Years - | National Cancer Institute (NCI) | |
| Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) | NCT06400264 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Nivolumab Relatlimab | 18 Years - | National Cancer Institute (NCI) | |
| Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | NCT03925428 | Advanced Lympho... Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Refractory B-Ce... Refractory Lymp... Refractory Mali... Refractory Panc... Refractory T-Ce... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Entinostat Molibresib | 12 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
